There were also no significant differences in the rate of SARS-CoV-2 infection between the patients with psoriasis receiving IL-17 inhibitors and those receiving non-biologics in the children group (RR: 12.83; 95% CI: 0.72-227.78; P = 0.08) and the NA group (RR: 0.98; 95% CI: 0.55-1.75; P = 0.94), respectively (Figure 4A). The gene discussed is IL17A; the disease is psoriasis.